CD274 and neoplasm: A further sub-analysis in strong PD-L1-positive tumors (i.e., >50%) has confirmed the axiom “more PD-L1 expression on tumor and more nivolumab clinical activity.” There are many reasons to consider PD-L1 expression as a weak predictive biomarker.